19.10 Stereochemistry in Drug Development
Basics of Organic Chemistry
In the synthesis of pharmaceutical products chirality is a critical feature to determine safety and efficacy. Because biological system are composed of chiral building block drug receptors which function as highly specific “chiral locks”. Consequently, the two enantiomers of a chiral drug often exhibit vastly different potentials and profiles.
Thalidomide, a tranquilliser was originally distributed as racemic mixture Figure 19.7. It seemed to be a very successful, non-toxic sedative with no known side-effects. In the early 1960s, however, it was discovered that women who had been prescribed the sedative to treat the nausea ('morning sickness') in early pregnancy had produced badly deformed babies. The drug was immediately withdrawn.
Research showed that whilst the (+) isomer was an effective and safe tranquilliser, the (-) isomer was the culprit in damaging the fetus. Originally it was thought that the problem had been due to contamination by the (-) isomer in some production batches, but subsequent research has shown that racemisation of the pure (+) isomer occurs rapidly as soon as it enters the blood stream. Within 10 minutes racemisation is over 50% complete. Thalidomide will never be marketed again, although analogues, that are chirality stable are being, investigated as possible anti-inflammatory drugs.